Abstract
The only part of an antigen (a protein molecule found on the surface of a pathogen) that is composed of epitopes specific to T and B cells is recognized by the human immune system (HIS). Identification of epitopes is considered critical for designing an epitope-based peptide vaccine (EBPV). Although there are a number of vaccine types, EBPVs have received less attention thus far. It is important to mention that EBPVs have a great deal of untapped potential for boosting vaccination safety—they are less expensive and take a short time to produce. Thus, in order to quickly contain global pandemics such as the ongoing outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), as well as epidemics and endemics, EBPVs are considered promising vaccine types. The high mutation rate of SARS-CoV-2 has posed a great challenge to public health worldwide because either the composition of existing vaccines has to be changed or a new vaccine has to be developed to protect against its different variants. In such scenarios, time being the critical factor, EBPVs can be a promising alternative. To design an effective and viable EBPV against different strains of a pathogen, it is important to identify the putative T- and B-cell epitopes. Using the wet-lab experimental approach to identify these epitopes is time-consuming and costly because the experimental screening of a vast number of potential epitope candidates is required. Fortunately, various available machine learning (ML)-based prediction methods have reduced the burden related to the epitope mapping process by decreasing the potential epitope candidate list for experimental trials. Moreover, these methods are also cost-effective, scalable, and fast. This paper presents a systematic review of various state-of-the-art and relevant ML-based methods and tools for predicting T- and B-cell epitopes. Special emphasis is placed on highlighting and analyzing various models for predicting epitopes of SARS-CoV-2, the causative agent of COVID-19. Based on the various methods and tools discussed, future research directions for epitope prediction are presented.
Highlights
An antigenic determinant (AD) is a portion of an antigen molecule known as an epitope that is recognized by the human immune system, by antibodies or T and B cells [1]
A review has been provided for the state of-the-art machine learning (ML)-based tools that are available online and free to use for researchers working in vaccine design
It is important to mention here that the application of epitope prediction tools/methods to SARS-CoV-2 presented in this review is not satisfactorily developed, and only a few them have been applied for SARS-CoV-2 epitope prediction
Summary
An antigenic determinant (AD) is a portion of an antigen molecule known as an epitope that is recognized by the human immune system, by antibodies or T and B cells [1]. COVID-19 can be severe and has caused millions of deaths around the world It is a respiratory illness and affects people according to the physiology and immune system of the human body. Due to the rate at which SARS-CoV-2 is circulating in the population, thereby causing unprecedented infections, its chances of mutating more and more have increased . The variant B.1.617.2, named Delta [3], first identified during a serious wave of COVID-19 infections in India in April and May 2021 [4], was declared a variant of concern (VOC) by the “US Centers for Disease Control and Prevention (CDC)” on 15 June 2021 [5]. The receptor binding domain (RBD) which is involved in the interactions with human angiotensin-converting enzyme-2 (ACE-2) receptor and causes infection leading to the COVID-19 comprised 44 mutations that included residues within 3.2 Å interacting distance from the ACE-2 receptor”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.